112 Chapter 5 Table S3. Comorbidities Cases (n = 316) Controls (n = 632) P value Myocardial infarction 33 (10.4) 67 (10.6) >0.99 Congestive heart failure 38 (12.0) 83 (13.2) 0.70 Peripheral vascular disease 19 (6.0) 43 (6.8) 0.74 Cerebrovascular accident 26 (8.2) 66 (10.5) 0.33 Dementia 5 (1.6) 19 (3.0) 0.27 Chronic pulmonary disease 64 (20.3) 112 (17.7) 0.40 Connective tissue disease 7 (2.2) 11 (1.7) 0.80 Peptic ulcer disease 9 (2.8) 28 (4.4) 0.31 Renal disease 33 (10.4) 55 (8.7) 0.46 Mild liver disease 1 (0.3) 22 (3.5) 0.01 Moderate to severe liver disease 7 (2.2) 17 (2.7) 0.82 Diabetes without end-organ damage 47 (14.9) 88 (13.9) 0.78 Diabetes with end-organ damage 15 (4.7) 50 (7.9) 0.09 Hemiplegia 8 (2.5) 21 (3.3) 0.64 Leukemia 4 (1.3) 2 (0.3) 0.19 Lymphoma 4 (1.3) 7 (1.1) >0.99 Solid tumor without metastasis 33 (10.4) 62 (9.8) 0.85 Solid tumor with metastasis 13 (4.1) 24 (3.8) 0.96 Acquired Immune Deficiency Syndrome 2 (0.6) 2 (0.3) 0.86 Immunosuppression 25 (7.9) 28 (4.4) 0.04 Data are n (%). Continuous nonparametric data were analyzed using a Wilcoxon signed rank sum- or Kruskal-Wallis test; categorical data were analyzed using a Fisher exact test; continuous parametric data were analyzed using a Student t test; a P value < 0.05 was considered statistically significant.
RkJQdWJsaXNoZXIy MTk4NDMw